



DRUG-DRUG INTERACTIONS (13)

Drug	Possible Mechanism / Onset and severity	Adverse Effects	Management			
Drugs that DECREASE tacrolimus (TAC) levels						
Anticonvulsants: > Phenytoin > Carbamazepine > phenobarbital, primidone	Enzyme induction TAC metabolism • delayed / major • delayed/ moderate • delayed / major	↓effectiveness of TAC which may lead to rejection	↑ TAC dose by 30% and monitor levels following addition, dose change or discontinuation			
Antimicrobial: > rifampin > caspofungin	Induction of hepatic enzymes • delayed / major Mechanism is unknown • delayed / moderate	↓effectiveness of TAC which may lead to rejection	Monitor TAC levels following addition, dose change or discontinuation. Monitor tacrolimus level closely when capsofungin is initiated or			
	- delayed / moderate		dose changes and when capsofungin is discontinued.			





Drug	Possible Mechanism / Onset and severity	Adverse Effects	Management			
B) Drugs that INCREASE tacrolimus (TAC) levels						
Antimicrobial: Perythromycin, clarithromycin	↓TAC metabolism, ↑rate of absorption, ↓volume of distribution • delayed / major	↑TAC levels, ↑ risk of toxicity	Monitor TAC levels following addition, dose change or discontinuation. Monitor serum creatinine			
 azole antifungals (fluconazole, ketoconazole, itraconazole, posaconazole, voriconazole) 	↓TAC metabolism • delayed/ moderate					
Antidepressants: fluoxetine, fluvoxamine greater than sertraline, venlafaxine, mirtazapine, paroxetine	↓TAC metabolism • delayed/ moderate	↑TAC levels, ↑ risk of toxicity	Consider another antidepressant (citalopram, escitalopram) and/or monitor TAC levels closely			
Cardiovascular: > diltiazem, verapamil > amiodarone	May inhibit hepatic metabolism of TAC •delayed / Major	↑TAC levels, ↑ risk of toxicity	Monitor TAC levels following addition, dose change or discontinuation			



PHARMACODYNAMIC INTERACTIONS (13)

Drug	Proposed Mechanism and Possible effects		Management			
Pharmacodynamic Interactions of Tacrolimus (TAC)						
 Aminoglycosides, Amphotericin B, NSAIDS, COX-2 inhibitors 	Additive nephrotoxicity	These drugs should be avoided in transplant recipients due to increased nephrotoxicity. The only exception is when the benefit clearly outweighs the potential risks and only used for short-term treatment. Renal function should be monitored closely while this drug is used				
HMG-CoA Reductase Inhibitors: Example: Iovastatin, simvastatin, atorvastatin	TAC may ↓metabolism of these agents →accumulation of statin and toxicity: Myalgia, myopathy, rhabdomyolysis	Start with low dose of these agents and monitor very closely for toxicity				
➤ Digoxin	↓volume of distribution of digoxin by 50-70%, ↑⟨digoxin half-life by 30-40%, and increased digoxin levels Digoxin toxicity such as vomiting, cardiac arrhythmia's	Initiate low dose and follow up with serum digoxin levels Closely monitor for symptoms of digoxin toxicity				

